The reporter learned from Liangjiang New Area that the self-developed product “salmetroticasone inhalation powder” by Runsheng Pharmaceutical Co., Ltd. located in Shuitu Xincheng has been officially approved for marketing by the US Food and Drug Administration. This is also the first inhalation powder product independently developed by a Chinese company and certified by the FDA. According to reports, the two approved specifications of this product include 100/50mcg and 250/50mcg; this product is in the form of combination medication and is specially used for regular treatment of reversible airway obstructive diseases such as asthma in adults and children. Among them, the 250/50mcg specification can also be used for maintenance treatment of COPD. The product was declared for sale in the domestic market in 2025, and is currently undergoing the review and approval process by the State Drug Administration. After the product is launched, it will serve more than 45 million domestic asthma patients and 100 million patients with chronic obstructive pulmonary disease, further guaranteeing medication for patients with respiratory diseases in China.

The reporter learned from Liangjiang New Area that the self-developed product “salmetroticasone inhalation powder” by Runsheng Pharmaceutical Co., Ltd. located in Shuitu Xincheng has been officially approved for marketing by the US Food and Drug Administration. This is also the first inhalation powder product independently developed by a Chinese company and certified by the FDA. According to reports, the two approved specifications of this product include 100/50mcg and 250/50mcg; this product is in the form of combination medication and is specially used for regular treatment of reversible airway obstructive diseases such as asthma in adults and children. Among them, the 250/50mcg specification can also be used for maintenance treatment of COPD. The product was declared for sale in the domestic market in 2025, and is currently undergoing the review and approval process by the State Drug Administration. After the product is launched, it will serve more than 45 million domestic asthma patients and 100 million patients with chronic obstructive pulmonary disease, further guaranteeing medication for patients with respiratory diseases in China.